AC Immune (NASDAQ:ACIU - Get Free Report)'s stock had its "buy" rating reissued by HC Wainwright in a report released on Thursday,Benzinga reports. They presently have a $16.00 price target on the stock.
AC Immune Price Performance
Shares of ACIU stock traded down $0.04 during mid-day trading on Thursday, hitting $1.55. The company had a trading volume of 89,054 shares, compared to its average volume of 325,706. The stock's 50 day moving average price is $2.37 and its 200-day moving average price is $2.84. AC Immune has a 52-week low of $1.50 and a 52-week high of $4.98. The company has a market capitalization of $155.64 million, a P/E ratio of -3.37 and a beta of 1.49.
Institutional Investors Weigh In On AC Immune
Large investors have recently made changes to their positions in the company. Squarepoint Ops LLC purchased a new position in AC Immune during the 4th quarter valued at approximately $118,000. Two Sigma Advisers LP bought a new position in shares of AC Immune during the 4th quarter valued at approximately $36,000. Cantor Fitzgerald L. P. purchased a new position in shares of AC Immune in the fourth quarter valued at $68,000. Jane Street Group LLC bought a new stake in AC Immune in the fourth quarter worth $66,000. Finally, Northern Trust Corp bought a new stake in AC Immune in the fourth quarter worth $1,088,000. 51.36% of the stock is owned by institutional investors.
About AC Immune
(
Get Free Report)
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases.
Further Reading
Before you consider AC Immune, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AC Immune wasn't on the list.
While AC Immune currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
